Tagrisso cardiotoxicity – an interesting case
Dr Arjun K Ghosh, Consultant Cardiologist, Barts Heart Centre and University College London Hospital
Tagrisso cardiotoxicity overview
Dr Arjun K Ghosh, Consultant Cardiologist, Barts Heart Centre and University College London Hospital
Stage IIB patient case study of adjuvant osimertinib
Dr Jason Chow, Consultant Medical Oncologist, St George’s Hospital
Severe reactions and warning signs
Dr David Rutkowski, Dermatology registrar and MRC clinical pharmacology fellow, NHS and University of Manchester
Introduction to EGFRi Skin toxicity
Dr David Rutkowski, Dermatology registrar and MRC clinical pharmacology fellow, NHS and University of Manchester
Management of skin toxicity
Dr David Rutkowski, Dermatology registrar and MRC clinical pharmacology fellow, NHS and University of Manchester
Tagrisso Case Study: First-Line EGFRm+ NSCLC – 45M
Dr Shobhit Baijal, Consultant Medical Oncologist, University Hospitals Birmingham
Tagrisso Case Study: First-line EGFRm+ NSCLC – 81F
Dr Ashley Cox, Consultant Clinical Oncologist Royal United Hospital Bath
Tagrisso Case Study: Second line EGFRm+ NSCLC – 63F
Dr David Woolf, Consultant Clinical Oncologist, Christie NHS Foundation Trust
Working with your patients to enhance their treatment pathway
Dr Gary Doherty, Consultant Medical Oncologist, Cambridge University Hospitals NHS Foundation Trust Ms Rachel Powell, Advanced Clinical Practitioner, University of Birmingham Hospitals NHS Foundation Trust
Tagrisso Case Study: First line EGFRm+ NSCLC – 84F
Dr Tom Newsom-Davis, Consultant Medical Oncologist, Chelsea and Westminster NHS Foundation Trust
Tagrisso Case Study: First line EGFRm+ NSCLC – 71F
Dr Tom Newsom-Davis, Consultant Medical Oncologist, Chelsea and Westminster NHS Foundation Trust
Tagrisso Case Study: First line EGFRm+ NSCLC – 76F
Dr David Woolf, Consultant Clinical Oncologist, Christie NHS Foundation Trust
Adjuvant setting case studies
Dr Marcus Remer, Consultant Medical Oncologist, Hampshire Hospitals NHS Foundation Trust
